SWISF - New to The Street Announces Six Business Interviews on its 524th Show Airing on the Fox Business Network Monday October 23 2023 at 10:30 PM PT | Benzinga
NEW YORK, Oct. 20, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a national TV show, announces episode 524th airing on the Fox Business Network, Monday, October 23, 2023, at 10:30 PM PT.
New to The Street's 524th TV episode line-up features the following six (6) business interviews:
1). Pet Health – PetVivo Holdings, Inc.'s (NASDAQ:PETV) (NASDAQ:PETVW) () interview with John Lai, CEO/President.
2). Biopharmaceutical – Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) () interview with David Luci, President/CEO.
3). Space Travel Medicines - Vector Space Biosciences, Inc.'s (SBIO) interview with Kasian Franks, CEO and Co-Founder.
4). Women's Healthcare – Aspira Women's Health, Inc.'s (NASDAQ:AWH) () interviews with Nicole Sandford, President, CEO, and Board Member, and Dr. Tamika Sea, FACOG, obstetrician, gynecologist and Founder/Owner of Advanced Women's Care Center.
5). European Business Growth - Bocconi University – SDA Bocconi School of Management's interviews with Stefano Caselli, Dean of SDA Bocconi School of Management, and Jean Maria, CEO/Founder of UCapital.
6). "Sekur Privacy & Sekur Security Segment – The Weekly Hack" interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX:SWISF) (CSE:SKUR) (FRA: GDT0) () (Sekur®).
Episode #524
From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with John Lai, CEO/President of PetVivo Holdings, Inc.'s (NASDAQ:PETV) (NASDAQ:PETVW) () ("PetVivo") about the Company. PetVivo manufactures, commercializes, and licenses innovative medical devices and pet therapeutics. John talks about the Company attending the American College of Veterinary Surgeons (ACVS) annual conference. During the Conference, Ethos Veterinary Health presented data from a study on PETV's patented product, Spryng with OsteoCushion Technology ("Spryng"), an intra-articular injectable veterinary medical device. The study demonstrated the efficacy of Spryng as an excellent, non-invasive alternative in treating dogs with cranial cruciate disease and injuries. Spryng is a naturally derived matrix of building proteins that mimics collagen tissue, significantly improving animals with cruciate damage and disease. The study showed that animals had a 25% or greater reduction in pain when injected, a significant measurement used in determining effective treatments. Veterinarians see positive post-surgery rehabilitation for animals needing corrective surgery when using Spryng. John informs viewers that a pet's quality of life and cost of therapy are pet owners' concerns; Spryng is a reasonable treatment, reducing pain, and pet insurance covers the product use. John believes as more published studies prove the viability of Spryng, more veterinarians will adopt it as a front-line treatment. The Company expects to release study data on Spryng on cats once available. PETV's Spryng is becoming more widely known as an effective disruptive technology for treating dogs, horses, and cats with osteoarthritis. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. - https://petvivo.com/ & Spryng with OsteoCushion Technology - https://www.sprynghealth.com/.
David Luci, the President/CEO at Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) (), is at the Nasdaq Marketsite Studio, talking with New to The Street's TV Host Jane King about the Company. Acurx Phamaceuticals, Inc. is a clinical-stage biopharmaceutical business developing a new class of antibiotics for life-threatening bacterial infections. David explains the significance of the Company's successful discontinuation of its Phase 2b clinical trial of its lead antibiotic candidate, Ibezapolstat drug, for treating patients with Clostridioides difficile Infections (CDI). Management expects to move forward with Phase 3 clinical trials with the expectation of an FDA approval in 2026. David believes the Company stock is up because of the published news about the Company's completion of the Phase 2b trial. Globally, health organizations are expressing the immediate need for a new class of antibacterial drugs because the current decades-old treatments are not working. CDI kills thousands of people annually, with many catching the infection in hospitals and nursing homes. Acrux Pharmaceuticals, Inc., with its pipeline of drugs, seeks cures for some of the deadliest bacteria. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.
New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio sits with Kasian Franks, CEO and Co-Founder of Vector Space Biosciences, Inc. (SBIO) ("Vector"). The Company focuses on the development of precision medicines to help humans overcome problems associated with space travel. Kasian tells viewers that until humankind can provide helpful and precision bioscience drugs to overcome microgravity and radiation exposures, colonization on the Moon and Mars cannot ensue. Vector, through its three divisions, a biosciences lab, AI/language modeling & discovery lab, and a CubeSat hardware lab, can create and design specific experiments for biotechs, pharmas, and materials companies. The experimental outcomes provide scientific data for developing new materials, repurposing existing drugs, and developing and creating new forms of precision drugs for space travel and earthly uses. Kasian explains how its AI and language modeling uses data collected and transmitted from a low orbit launched CubeSat sent to Microsoft Azure Space's platform. Taking the data and adding AI, scientists are making new and exciting discoveries with hopeful countermeasures needed to create medicines to protect and heal humans during spaceflights, landing missions, long-term base habitation, and here on Earth. The on-screen QR code is available during the show; download ...